Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety

CME
25/03/2025

Listen "Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety "

Descargar episodio Ver en sitio original

Episode Synopsis



Host: Aditya Bardia, MD

Host: Tiffany Traina, MD, FASCO



When choosing an antibody-drug conjugate (ADC) for the second-line treatment of triple-negative breast cancer (TNBC), efficacy, sequencing, and management of toxicities are key. Do you know how best to choose a therapy for your patients? Our experts have the answers and strategies you need!

More episodes of the podcast CME

Updates in Major Depressive Disorder with Insomnia 07/11/2025
Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis 03/10/2025
Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers 30/09/2025
Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers 30/09/2025
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers 30/09/2025
Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer 30/09/2025
From Resistance to Response: Evolving Strategies in MDD Management 26/09/2025
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 26/09/2025
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025 26/09/2025
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 26/09/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA